Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.82 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.64 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12852171 | 0.91 | S1PR1 (0.84) | S1PR1S1PR3S1PR5KCNH2CYP3A4 | |
| SCHEMBL2602116 | 0.90 | S1PR1 (1.00) | S1PR1S1PR3S1PR5 | |
| SCHEMBL3660540 | 0.90 | S1PR1 (0.82) | S1PR1S1PR3S1PR5KCNH2CYP3A4 | |
| Hydrochloric Acid SCHEMBL3068164 | 0.90 | S1PR1 (0.98) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2123300 | 0.90 | S1PR1 (0.79) | S1PR1S1PR3S1PR5KCNH2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL2122658 | 0.88 | S1PR1 (0.92) | S1PR1S1PR3S1PR5 | |
| Formic Acid SCHEMBL3660538 | 0.88 | S1PR1 (0.94) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2123471 | 0.88 | S1PR1 (0.71) | S1PR1S1PR3S1PR5KCNH2 | |
| SCHEMBL2122165 | 0.88 | S1PR1 (0.75) | S1PR1S1PR3S1PR5KCNH2CYP3A4 | |
| SCHEMBL2122626 | 0.86 | S1PR1 (0.85) | S1PR1S1PR3S1PR5KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443110-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010146105-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146105-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.